Rallybio to Merge With Candid Therapeutics in $500M-Backed Reverse Merger

Rallybio Corporation (NASDAQ: RLYB) has agreed to merge with privately held Candid Therapeutics in a reverse merger that will create a newly capitalized, Nasdaq-listed biotech focused on T-cell engager (TCE) therapies for autoimmune diseases.

Upon closing, the combined company will operate under the name Candid Therapeutics, Inc. and is expected to trade under the ticker CDRX.

A Major Capital Infusion

In connection with the transaction, Candid secured more than $505 million in oversubscribed private financing from a syndicate of leading healthcare investors. The capital raise is expected to fund operations into 2030 and support multiple clinical-stage programs.

The financing strength is notable in the current biotech funding environment and provides the new company with a significant runway to advance its autoimmune T-cell engager pipeline.

Strategic Shift for Rallybio Shareholders

The merger represents a full strategic pivot for Rallybio. Following the transaction:

• Candid shareholders and new investors will own approximately 96% of the combined company.
• Existing shareholders will retain a minority equity stake.
• Investors will also receive contingent value rights (CVRs) tied to potential proceeds from legacy asset sales.

Effectively, Rallybio becomes a public vehicle for Candid’s pipeline and management team, with substantial capital backing.

Investment Thesis: T-Cell Engagers Beyond Oncology

T-cell engager therapies have gained traction in oncology, and Candid is applying this modality to autoimmune diseases. The company’s programs aim to selectively target pathogenic B cells implicated in conditions such as myasthenia gravis and inflammatory lung diseases.

If successful, this approach could position Candid at the forefront of next-generation immunology therapies, a market with significant unmet need and commercial potential.

Key Risks and Considerations

Investors should monitor:

• Execution of planned Phase 2 trials
• Safety and tolerability data for autoimmune applications
• Cash burn trajectory despite strong financing
• Broader biotech market conditions

Reverse mergers can create volatility, especially as ownership structures shift and legacy programs are phased out.

Bottom Line

The merger between Rallybio and Candid Therapeutics creates a well-capitalized public biotech centered on autoimmune T-cell engager therapies. With over $500 million in fresh funding, the combined company enters the public markets with substantial runway and a focused clinical strategy.

For current shareholders, the deal represents both dilution and opportunity — a reset built around a new pipeline, new leadership, and a long-term autoimmune immunotherapy thesis.